SAN DIEGO, Aug. 9, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the chief in backbone know-how innovation, centered on remodeling backbone surgical procedure with minimally disruptive, procedurally built-in options, at present introduced the resignation of Massimo Calafiore, govt vp and chief industrial officer, efficient August 31, 2022, to turn into the chief govt officer of a privately-held, orthopedics know-how firm. Upon Mr. Calafiore’s resignation, his duties might be reallocated amongst present members of administration whereas the Firm aligns its industrial construction to its long-term technique.
“On behalf of the NuVasive group, I want to thank Massimo for his affect on our group,” stated Chris Barry, chief govt officer. “He has completed a lot throughout his tenure at NuVasive and we want him nice success in his new alternative.”
Mr. Calafiore acknowledged, “In my 5 years at NuVasive, I’m very happy with our collective work to rework surgical procedure, advance care and most significantly—change the lives of sufferers around the globe. NuVasive is an incredible firm, and I’m excited to see what it’s going to accomplish by means of bringing world-class, revolutionary know-how to market.”
NuVasive, Inc. (NASDAQ: NUVA) is the chief in backbone know-how innovation, with a mission to rework surgical procedure, advance care, and alter lives. The Firm’s less-invasive, procedurally built-in surgical options are designed to ship reproducible and clinically confirmed outcomes. The Firm’s complete procedural portfolio consists of surgical entry devices, spinal implants, fixation programs, biologics, software program for surgical planning, navigation and imaging options, magnetically adjustable implant programs for backbone and orthopedics, and intraoperative neuromonitoring know-how and repair choices. With greater than $1 billion in web gross sales, NuVasive operates in additional than 50 international locations serving surgeons, hospitals, and sufferers. For extra data, please go to www.nuvasive.com.
NuVasive cautions you that statements included on this information launch that aren’t an outline of historic details are forward-looking statements that contain dangers, uncertainties, assumptions and different components which, if they don’t materialize or show appropriate, might trigger NuVasive’s outcomes to vary materially from historic outcomes or these expressed or implied by such forward-looking statements. The potential dangers and uncertainties which contribute to the unsure nature of those statements embrace, amongst others, dangers related to acceptance of the Firm’s surgical merchandise and procedures by backbone surgeons and hospitals, growth and acceptance of latest merchandise or product enhancements, medical and statistical verification of the advantages achieved through the usage of NuVasive’s merchandise, the Firm’s potential to adequately handle stock because it continues to launch new merchandise, its potential to recruit and retain administration and key personnel, and the opposite dangers and uncertainties described in NuVasive’s information releases and periodic filings with the Securities and Trade Fee. NuVasive’s public filings with the Securities and Trade Fee can be found at www.sec.gov. NuVasive assumes no obligation to replace any forward-looking assertion to replicate occasions or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.